Literature DB >> 10950842

Oxidation of the novel oxazolidinone antibiotic linezolid in human liver microsomes.

M A Wynalda1, M J Hauer, L C Wienkers.   

Abstract

In vitro studies were conducted to identify the hepatic enzyme(s) responsible for the oxidative metabolism of linezolid. In human liver microsomes, linezolid was oxidized to a single metabolite, hydroxylinezolid (M1). Formation of M1 was determined to be dependent upon microsomal protein and NADPH. Over a concentration range of 2 to 700 microM, the rate of M1 formation conformed to first-order (nonsaturable) kinetics. Application of conventional in vitro techniques were unable to identify the molecular origin of M1 based on the following experiments: a) inhibitor/substrates for various cytochrome P-450 (CYP) enzymes were unable to inhibit M1 formation; b) formation of M1 did not correlate (r(2) < 0.23) with any of the measured catalytic activities across a population of human livers (n = 14); c) M1 formation was not detectable in incubations using microsomes prepared from a baculovirus insect cell line expressing CYPs 1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 3A4, 3A5, and 4A11. In addition, results obtained from an in vitro P-450 inhibition screen revealed that linezolid was devoid of any inhibitory activity toward the following CYP enzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4). Additional in vitro studies excluded the possibility of flavin-containing monooxygenase and monoamine oxidase as potential enzymes responsible for metabolite formation. However, metabolite formation was found to be optimal under basic (pH 9.0) conditions, which suggests the potential involvement of either an uncharacterized P-450 enzyme or an alternative microsomal mediated oxidative pathway.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10950842

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  20 in total

1.  A case of lactic acidosis induced by linezolid.

Authors:  Juan Carlos Q Velez; Michael G Janech
Journal:  Nat Rev Nephrol       Date:  2010-04       Impact factor: 28.314

2.  Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis.

Authors:  Paolo Denti; Anneke C Hesseling; Louvina E van der Laan; Anthony J Garcia-Prats; H Simon Schaaf; Tjokosela Tikiso; Lubbe Wiesner; Mine de Kock; Jana Winckler; Jennifer Norman; Helen McIlleron
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

Review 3.  Pharmacological issues of linezolid: an updated critical review.

Authors:  Antonello Di Paolo; Paolo Malacarne; Emanuele Guidotti; Romano Danesi; Mario Del Tacca
Journal:  Clin Pharmacokinet       Date:  2010-07       Impact factor: 6.447

4.  The preclinical pharmacokinetic disposition of a series of perforin-inhibitors as potential immunosuppressive agents.

Authors:  M R Bull; J A Spicer; K M Huttunen; W A Denny; A Ciccone; K A Browne; J A Trapani; N A Helsby
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-08-26       Impact factor: 2.441

5.  Predictors of Inadequate Linezolid Concentrations after Standard Dosing in Critically Ill Patients.

Authors:  Max Taubert; Michael Zoller; Barbara Maier; Sebastian Frechen; Christina Scharf; Lesca-Miriam Holdt; Lorenz Frey; Michael Vogeser; Uwe Fuhr; Johannes Zander
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

6.  Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients.

Authors:  Tomohiro Sasaki; Hiroshi Takane; Katsuhiro Ogawa; Sayaka Isagawa; Takeshi Hirota; Shun Higuchi; Toshinobu Horii; Kenji Otsubo; Ichiro Ieiri
Journal:  Antimicrob Agents Chemother       Date:  2011-02-28       Impact factor: 5.191

7.  Population Pharmacokinetics and Dosage Optimization of Linezolid in Patients with Liver Dysfunction.

Authors:  Su-Hua Zhang; Zhen-Yu Zhu; Zi Chen; Ying Li; Yang Zou; Miao Yan; Yun Xu; Feng Wang; Mou-Ze Liu; Min Zhang; Bi-Kui Zhang
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

8.  Physiologically Based Pharmacokinetic Prediction of Linezolid and Emtricitabine in Neonates and Infants.

Authors:  Peng Duan; Jeffrey W Fisher; Kenta Yoshida; Lei Zhang; Gilbert J Burckart; Jian Wang
Journal:  Clin Pharmacokinet       Date:  2017-04       Impact factor: 6.447

9.  Comparative study of the effects of pyridoxine, rifampin, and renal function on hematological adverse events induced by linezolid.

Authors:  Alex Soriano; Mar Ortega; Sebastián García; Georgina Peñarroja; Albert Bové; Miguel Marcos; Juan C Martínez; José A Martínez; Josep Mensa
Journal:  Antimicrob Agents Chemother       Date:  2007-04-30       Impact factor: 5.191

Review 10.  Linezolid: in infants and children with severe Gram-positive infections.

Authors:  Katherine A Lyseng-Williamson; Karen L Goa
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.